Table 1 univariate analysis for overall, progression free survival and time to progression
From: Inhibition of Aurora A enhances radiosensitivity in selected lung cancer cell lines
| Â | Â | Overall Survival | Progression Free Survival | Time to Progression | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|  | Total cases | Died n = 20 | Alive n = 43 | Log-rank | Gehan test | Prog. n = 37 | Prog. free n = 26 | Log-rank | Gehan test | Prog. n = 34 | Prog. free n = 29 | Log-rank | Gehan test |
Age (years) | |||||||||||||
 ≥ 57 | 32 | 11 (55) | 21 (49) | 0.806 | 0.748 | 21 (57) | 11 (42) | 0.5057 | 0.2854 | 19 (56) | 13 (45) | 0.664 | 0.302 |
 < 57 | 31 | 9 (45) | 22 (51) |  |  | 16 (43) | 15 (58) |  |  | 15 (44) | 16 (55) |  |  |
Gender, n (%) | |||||||||||||
 Female | 16 | 7 (35) | 9 (20) | 0.358 | 0.643 | 11 (30) | 5 (19) | 0.405 | 0.4016 | 10 (29) | 6 (21) | 0.499 | 0.424 |
 Male | 47 | 13 (65) | 34 (79) |  |  | 26 (70) | 21 (71) |  |  | 24 (74) | 23 (79) |  |  |
Pathology, n (%) | |||||||||||||
 SCC | 32 | 10 (50) | 22 (51) | 0.982 | 0.953 | 19 (51) | 13 (50) | 0.832 | 0.663 | 17 (50) | 15 (52) | 0.928 | 0.596 |
 ADC | 31 | 10 (50) | 21 (49) |  |  | 18 (49) | 13 (50) |  |  | 17 (50) | 14 (48) |  |  |
Lymph node metastasis, n (%) | |||||||||||||
 Pos | 29 | 15(75) | 14 (33) | 0.004** | 0.008** | 24 (65) | 5 (19) | 0.006* | 0.032* | 22 (65) | 7 (24) | 0.002** | 0.015* |
 Neg | 34 | 5 (25) | 29 (67) |  |  | 13 (35) | 21 (71) |  |  | 12 (35) | 22 (76) |  |  |
Stage, n (%) | |||||||||||||
 IA-IB | 20 | 2 (10) | 18 (42) | 0.049* | 0.049* | 7 (19) | 13 (50) | 0.001** | 0.006** | 7 (21) | 13 (45) | 0.000*** | 0.005** |
 IIA-IIB | 14 | 5 (25) | 9 (21) |  |  | 6 (16) | 8 (31) |  |  | 5 (15) | 9 (31) |  |  |
 IIIA-IIIB | 26 | 11 (55) | 15 (35) |  |  | 21 (57) | 5 (19) |  |  | 19 (56) | 7 (24) |  |  |
 IV | 3 | 2 (10) | 1 (2) |  |  | 3 (8) | 0 (0) |  |  | 3 (9) | 0 (0) |  |  |
Ki67, n (%) | |||||||||||||
 High | 39 | 18 (90) | 21 (49) | 0.001** | 0.002** | 27 (73) | 12 (46) | 0.004** | 0.006** | 25 (74) | 14 (48) | 0.014* | 0.012* |
 Low | 24 | 2 (10) | 22 (51) |  |  | 10 (27) | 14 (54) |  |  | 9 (26) | 15 (52) |  |  |
AURKA, n (%) | |||||||||||||
 High | 13 | 8 (40) | 5 (12) | 0.010* | 0.013* | 10 (27) | 3 (12) | 0.052 | 0.046* | 10 (29) | 3 (10) | 0.045* | 0.037* |
 Low | 50 | 12 (60) | 38 (88) |  |  | 23 (73) | 23 (88) |  |  | 24 (71) | 26 (90) |  |  |
P53, n (%) | |||||||||||||
 High | 27 | 11 (55) | 16 (37) | 0.154 | 0.107 | 15 (41) | 14 (54) | 0.439 | 0.562 | 13 (38) | 14 (48) | 0.669 | 0.785 |
 Low | 36 | 9 (45) | 27 (63) |  |  | 22 (59) | 12 (46) |  |  | 21 (62) | 15 (52) |  |  |
P21, n (%) | |||||||||||||
 High | 20 | 8 (40) | 12 (28) | 0.266 | 0.296 | 11 (30) | 9 (35) | 0.905 | 0.898 | 9 (26) | 11 (38) | 0.696 | 0.733 |
 Low | 43 | 12 (60) | 31 (72) |  |  | 26 (70) | 17 (65) |  |  | 25 (74) | 18 (62) |  |  |
P53 + AURKA, n (%) | |||||||||||||
 DP | 7 | 4 (20) | 3 (7) | 0.042* | 0.012* | 5 (13) | 2 (8) | 0.767 | 0.527 | 5 (15) | 2 (7) | 0.829 | 0.594 |
 SP | 26 | 11 (55) | 15 (35) |  |  | 15 (41) | 11 (42) |  |  | 13 (38) | 13 (45) |  |  |
 DN | 30 | 5 (25) | 25 (58) |  |  | 17 (46) | 13 (50) |  |  | 16 (47) | 14 (48) |  |  |